UM  > 健康科學學院
Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy
Qi Wang1; Man Luo1; Na We1; Alex Chang2; Kathy Qian Luo3
2019-09
Source PublicationMOLECULAR PHARMACEUTICS
ISSN1543-8384
Volume16Issue:9Pages:3873-3886
Abstract

Acetyltanshinone IIA (ATA), synthesized in our group exhibiting good anti-breast cancer effects, is expected to replace the commonly used anti-ER+ breast cancer (breast cancer cells overexpressing the estrogen receptor) drug tamoxifen. To promote the clinical progress of ATA, polyethylene glycol (PEG)- modified liposomes were used to encapsulate ATA along with improving its bioavailability and in vivo anticancer efficiency. The resulting liposomal ATA exhibited a spherical shape with an average size of 188.5 nm. In vitro evaluations showed that liposomal ATA retained the anti-breast cancer efficacy of ATA while exerting much less cytotoxicity toward noncancerous cells. Significantly, pharmacokinetics analysis showed that the AUC0−24h of liposomal ATA was 59 times higher than that of free ATA, demonstrating increased bioavailability of ATA. Preclinical experiments demonstrated that liposomal ATA reduced the growth of ER-positive human breast tumor xenografts by 73% in nude mice, and the liposomal ATA exhibited a much lower level of toxicity than that of free ATA with respect to zebrafish larval mortality, body formation, and heart function during development. Moreover, 7-day and 21-day tissue toxicity levels were determined in mice by intravenous administration of a maximum dosage of liposomal ATA (120 mg/kg). The results showed no obvious tissue damage in major organs, including the heart, liver, spleen, kidney, and brain. In summary, we have developed a clinical formulation of liposomal ATA with the high bioavailability and potent efficacy for the treatment of ER-positive breast cancer.

KeywordAnti-breast Cancer Drugs Acetyltanshinone Iia (Ata) Mpeg-liposomes Bioavailabilit Pharmacokinetics Toxicity Study
DOI10.1021/acs.molpharmaceut.9b00493
Indexed BySCI
Language英语
WOS Research AreaResearch & Experimental Medicine ; Pharmacology & Pharmacy
WOS SubjectMedicine, Research & Experimental ; Pharmacology & Pharmacy
WOS IDWOS:000484064800013
PublisherAMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
Fulltext Access
Citation statistics
Cited Times [WOS]:0   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorKathy Qian Luo
Affiliation1.School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore 637457
2.Department of Oncology, Johns Hopkins Singapore, Singapore 308433
3.Faculty of Health Sciences, University of Macau, Taipa, Macau, China
Corresponding Author AffilicationFaculty of Health Sciences
Recommended Citation
GB/T 7714
Qi Wang,Man Luo,Na We,et al. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy[J]. MOLECULAR PHARMACEUTICS,2019,16(9):3873-3886.
APA Qi Wang,Man Luo,Na We,Alex Chang,&Kathy Qian Luo.(2019).Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.MOLECULAR PHARMACEUTICS,16(9),3873-3886.
MLA Qi Wang,et al."Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy".MOLECULAR PHARMACEUTICS 16.9(2019):3873-3886.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Qi Wang]'s Articles
[Man Luo]'s Articles
[Na We]'s Articles
Baidu academic
Similar articles in Baidu academic
[Qi Wang]'s Articles
[Man Luo]'s Articles
[Na We]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Qi Wang]'s Articles
[Man Luo]'s Articles
[Na We]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.